Topic: Ligand Pharmaceuticals Inc.

Analysts at Summer Street Research started coverage on shares of Ligand Pharmaceutica (NASDAQ: LGND) in a research report issued to clients and...
Equities research analysts at Griffin Securities initiated coverage on shares of Ligand Pharmaceutica (NASDAQ: LGND) in a research note issued to...
Ligand Pharmaceutica (NASDAQ: LGND)'s stock had its "buy" rating reaffirmed by equities research analysts at McNicoll Lewis Vlak in a research...
Shares of Ligand Pharmaceuticals (LGND) have continued to climb since we first reported in August that insider buying in the stock was on the...
Posted on 10/10/11 at 3:15pm by Olivia Lange . McNicoll, Lewis & Vlak reiterated its Ligand Pharmaceuticals (NASDAQ: LGND ) Buy rating and $30...
Posted on 09/08/11 at 3:58am by Lisa Levin . On CNBC's Mad Money, Jim Cramer said during the Lightning Round that PriceSmart (NASDAQ: PSMT ) is a ...
Investors couldn't have missed seeing the recent waves of new corporate share buyback plans. What they may have not noticed as clearly is the...
Posted on 07/26/11 at 2:53pm by Olivia Lange . C.K. Cooper reiterated its Ligand Pharmaceuticals (NASDAQ: LGND ) Buy rating increased its Ligand...

Ligand Names Matthew W. Foehr COO

Posted on 04/18/11 at 4:17pm by Benzinga Staff . Ligand Pharmaceuticals Incorporated (NASDAQ: LGND ) announced that it has appointed Matthew W...
and Ligand Pharmaceuticals are anxiously awaiting a decision from a U.S. Food and Drug Administration's advisory board concerning the future of their promising osteoporosis drug Fablyn-a future that now looks more precarious.. The board said that while Fablyn has been ...